Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

This is an open-label, multicenter Phase 1b/2 study evaluating nanatinostat in

combination with valganciclovir alone and in combination with pembrolizumab. Nanatinostat

is a selective class I HDAC inhibitor which induces EBV early lytic phase protein

generation, activating (val)ganciclovir to its cytotoxic form.

The Phase 1b dose escalation portion is designed to evaluate safety and to determine the

recommended Phase 2 dose (RP2D) in patients with EBV+ RM-NPC followed by a Project

Optimus | FDA (https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus)

cohort to confirm the RP2D. Up to 60 patients with EBV+ RM-NPC will be randomized 1:1 to

receive nanatinostat in combination with valganciclovir at the confirmed RP2D with or

without pembrolizumab to evaluate safety, overall response rate, and potential

pharmacodynamic markers in the Phase 2 dose expansion part of the study. Additionally,

patients with other EBV+ solid tumors will be enrolled to receive nanatinostat in

combination with valganciclovir at the RP2D in a Phase 1b cohort.

The study was prematurely terminated after the end of Phase 1b and did not proceed to

Phase 2.